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Sexual practices before treatment ranged from masturbation, 
oral sex, and anal sex in order of frequency, and remained 
the same after treatment. Overall sexual satisfaction 
decreased, especially for participants with urinary 
incontinence and erectile dysfunction. Many men described 
orgasms after treatment as feeling 'incomplete' due to lack of 
ejaculate. Some single men or men in open relationships 
reported a loss of confidence or difficulty meeting other men 
after treatment. More information from physicians could have 
prepared participants to better cope with side effects; 
however, participants showed resilience by continuing to 
engage in sexual activities and had a positive view of their 
life after treatment. 
Conclusions: The adverse impact of PCa treatments on 
sexual function for MSM can be a barrier to developing new 
relationships. To fulfil the principle of informed consent, 
MSM should be made aware of how PCa treatments can affect 
their sex lives. We intend to continue this research in order 
to develop a validated questionnaire to study sexual quality 
of life in MSM with prostate cancer and help guide the best 
treatment choices when MSM are diagnosed with PCa. 
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Purpose/Objective: The association of androgen deprivation 
therapy (ADT) to radiotherapy (RT) improves prognosis in 
patients with high-intermediate risk prostate cancer (PC). 
Luteinising hormone-releasing hormone (LHRH) agonists are 
the standard of care in these patients even if this treatment 
is associated with several side effects. Chronic anemia due to 
ADT with LHRH agonists is one of these. However, analyses 
focused on the impact of adyuvant ADT on chronic anemia in 
patients with PC are lacking. In particular only few studies on 
the impact of different hormonal treatments (LH-RH agonists 
vs antiandrogen) or different durations of hormone therapy 
(short-term vs. long-term) on the blood count are available. 
The purpose of this analysis is to evaluate the impact of 
adjuvant ADT on anemia. 
Materials and Methods: Data of patients with PC at 
intermediate-high risk receiving RT plus adjuvant hormone 
therapy (intermediate risk: 6 months; high risk: 24 months) 
were collected. Hemoglobin level was assessed before 
treatment and then at 2 and 5 years after radiotherapy. 
Hemoglobin mean values were calculated and these were 
compared using t-test based on type of hormone therapy 
(LHRH agonists vs antiandrogen) and duration of hormone 
therapy (6 months vs. 2 years). 
Results: One hundred eighty-six patients were evaluated. 




Conclusions: In patients undergoing radiotherapy plus 
adjuvant hormonal therapy for PC, hemoglobin levels were 
significantly lower in the group treated with LH-RH agonists 
after 2 years. Similar values were recorded after 5 years but 
the difference was not statistically significant, probably 
because of the smaller sample size. In contrast, no difference 
was observed based on duration of adjuvant therapy. 
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Purpose/Objective: To compare two systems to calculate the 
lateral, longitudinal and vertical margins for expansion from 
CTV to PTV in prostate cancer patients. 
Materials and Methods: 29 consecutive prostate cancer 
patients treated with IMRT were included. A Cone Beam CT 
was performed the first 4 days of treatment. The average of 
the displacements regarding the reference image was 
determined and was checked by another CBCT in the fifth 
day. Subsequently a weekly CBCT test was performed 
For each patient the deviations values were obtained in the 
three directions and the average value and standard 
deviation of these errors was calculated (S>). To deal with 
random errors, the first 5 CBCT errors were corrected by 
subtracting the mean value of the systematic errors 
